Patent Term, Duration, and Maintenance Fees
Patent term defines the window of enforceable exclusivity that the U.S. patent system grants an inventor — and its precise calculation, along with the maintenance fee obligations required to preserve it, governs the practical commercial value of any granted patent. This page covers the statutory basis for patent term under Title 35 of the U.S. Code, how term adjustments and extensions operate, the schedule of maintenance fees administered by the United States Patent and Trademark Office (USPTO), and the decision points that determine whether a patent remains in force. The regulatory context for patent law shapes all of these calculations, particularly following structural changes introduced by the Uruguay Round Agreements Act of 1994 and the America Invents Act of 2011.
Definition and scope
A utility patent's term of protection is set by 35 U.S.C. § 154 at 20 years measured from the earliest effective U.S. filing date of the application. This replaced the pre-1995 regime, which measured a 17-year term from the date of grant. The shift to a filing-date calculation aligned U.S. law with the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) administered by the World Trade Organization.
Three distinct patent types carry different statutory terms:
- Utility patents — 20 years from the earliest claimed priority filing date (35 U.S.C. § 154(a)(2)), subject to maintenance fee payments and any applicable adjustments or extensions.
- Design patents — 15 years from the date of grant for applications filed on or after May 13, 2015 (amended by the Patent Law Treaties Implementation Act of 2012); 14 years from grant for earlier applications. Design patents carry no maintenance fees.
- Plant patents — 20 years from the filing date under 35 U.S.C. § 163, also with no maintenance fees.
Provisional patent applications do not mature into patents directly and do not themselves establish a patent term. A non-provisional application claiming priority to a provisional must be filed within 12 months; that 12-month period effectively consumes a portion of the 20-year term, since term runs from the filing date of the non-provisional (or any earlier non-provisional in a continuation chain).
How it works
Patent Term Adjustment (PTA)
USPTO examination delays can reduce the effective exclusivity period for a patentee. Congress addressed this through Patent Term Adjustment, codified at 35 U.S.C. § 154(b). PTA adds days to the grant-end date to compensate for specific USPTO delays, including:
- Failure to issue a first Office Action within 14 months of filing.
- Failure to respond to a reply within 4 months.
- Failure to issue a patent within 3 years of the actual filing date.
Applicant delays — such as filing a continuation, requesting a delay, or submitting a late reply — reduce the PTA calculation day-for-day. The USPTO publishes the PTA calculation on the face of each issued patent.
Patent Term Extension (PTE)
Separate from PTA, Patent Term Extension under 35 U.S.C. § 156 compensates pharmaceutical and medical device patent holders for regulatory review time consumed by FDA premarket approval processes. The maximum PTE is 5 years, and the total remaining term after extension cannot exceed 14 years from FDA approval. PTE applies to a single patent per approved product and requires a formal application to the USPTO within 60 days of FDA approval.
Maintenance Fees
To keep a utility patent in force past the 4-year mark, the patent owner must pay maintenance fees to the USPTO at three intervals after grant:
| Fee Stage | Due at (post-grant) | Large Entity Fee (as of USPTO fee schedule) |
|---|---|---|
| First maintenance fee | 3.5 years | See USPTO Fee Schedule |
| Second maintenance fee | 7.5 years | See USPTO Fee Schedule |
| Third maintenance fee | 11.5 years | See USPTO Fee Schedule |
Each fee stage includes a 6-month grace period with a surcharge. Failure to pay within the grace period results in expiration of the patent. Expired patents can be revived through a petition showing the delay was unintentional, but revival is not guaranteed and involves additional fees (37 C.F.R. § 1.378).
Small entities (qualifying under 37 C.F.R. § 1.27) pay 60% of large entity fees; micro entities (qualifying under 35 U.S.C. § 123) pay 40% of large entity fees.
Common scenarios
Continuation and continuation-in-part chains. A continuation application shares the parent's filing date for term purposes. A patent issuing from a continuation filed 8 years after the original priority date has, at most, 12 years of remaining term from grant — and often less. Patent portfolio management under /patent-portfolio-management must account for term compression in continuation strategies.
Pharmaceutical pipeline patents. A compound patent filed at the time of discovery may face 10 or more years of FDA clinical trials and review before approval. PTE under § 156 is the primary mechanism to recover that regulatory lag, but the 14-year post-approval cap limits recovery for products with long prosecution histories.
Lapsed patents and competitive entry. A patent that expires due to nonpayment of maintenance fees at the 7.5-year stage enters the public domain immediately. Competitors may begin manufacturing and selling the previously protected invention without liability from that expiration date forward. The patent exhaustion doctrine further limits downstream enforcement even on in-force patents.
Submarine patent risk (pre-1995 filings). Applications filed before June 8, 1995, could claim either a 17-year-from-grant or 20-year-from-filing term, whichever was longer. This transitional rule, implemented under the Uruguay Round Agreements Act, is relevant only for the small universe of patents still alive from that era.
Decision boundaries
Several threshold determinations govern how patent term operates in practice:
Filing date versus priority date. The 20-year clock runs from the earliest effective filing date in the U.S., not the foreign priority date claimed under the Paris Convention. A U.S. application claiming foreign priority under 35 U.S.C. § 119 still measures its term from the U.S. filing date. For applications entering the national phase under the Patent Cooperation Treaty, term runs from the international filing date.
PTA eligibility boundaries. PTA does not apply to design patents, plant patents, or reissue applications. Inter partes review proceedings at the Patent Trial and Appeal Board do not toll or extend the underlying patent's term.
PTE versus PTA — mutual exclusivity. A patent owner may not stack PTE and PTA for the same delay period. Under 35 U.S.C. § 154(b)(2)(C), PTA is reduced by any period that overlaps with a PTE grant.
Entity status accuracy. Incorrectly claiming small or micro entity status to pay reduced maintenance fees constitutes inequitable conduct and can render the patent unenforceable. Patent owners must verify continued eligibility at each maintenance fee stage, not only at filing.
Terminal disclaimers. When the USPTO issues an obviousness-type double patenting rejection, applicants often file a terminal disclaimer that limits the patent's term to expire no later than a related patent. This creates an artificial ceiling on term that runs independently of the § 154 calculation. Terminal disclaimers are recorded with the USPTO and bind all successors in title.
The full overview of patent rights available through the USPTO requires understanding term as the foundational limit on enforceability — every downstream question about licensing, infringement suits, and portfolio valuation depends on whether a patent is in force and for how long.